CD20 Positive clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
open to eligible people ages 18-70
This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or…
at UCLA
Our lead scientists for CD20 Positive research studies include Sarah M. Larson, MD.
Last updated: